Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proofreading01:43

Proofreading

61.6K
Overview
61.6K
Proofreading01:31

Proofreading

9.2K
Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore,  it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase...
9.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.4K
Mismatch Repair01:36

Mismatch Repair

43.9K
Overview
43.9K
Mismatch Repair01:20

Mismatch Repair

6.7K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.7K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

8.1K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between hypertension and sepsis-related complications: a retrospective nationwide inpatient sample database cross-sectional study.

BMC infectious diseases·2026
Same author

Potential drug-drug interactions and 30-day mortality in ICU patients with bloodstream infection: a single-center retrospective study.

BMC infectious diseases·2026
Same author

Development and Validation of a Nomogram to Predict Multidrug-Resistant Organism Infection in Severe Pneumonia: A Retrospective Cohort Study.

International journal of general medicine·2026
Same author

The relationship between serum levels of miR-342 and miR-148a and acute lung injury in sepsis patients.

Open medicine (Warsaw, Poland)·2026
Same author

Human papillomavirus vaccination and herpes simplex virus infection: A cross-sectional analysis of young women in the United States.

International journal of STD & AIDS·2025
Same author

Comprehensive assessment of land degradation in the Sanjiangyuan region based on multi-source indicators.

Scientific reports·2025

Related Experiment Video

Updated: Feb 19, 2026

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
03:25

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy

Published on: June 16, 2022

1.4K

ERRATUM.

Ting Zhang, Lei Ye, Qizhi He

    Oncology Research
    |November 4, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Herpesvirus entry mediator (HVEM) is elevated in ovarian cancer, contributing to immune suppression. Silencing HVEM in ovarian cancer cells enhances T-cell activity and anti-tumor immune responses, suggesting HVEM as a potential immunotherapy target.

    More Related Videos

    Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
    09:41

    Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

    Published on: June 17, 2014

    12.5K
    Surgical Correction for Pediatric Epiblepharon and Trichiasis
    03:59

    Surgical Correction for Pediatric Epiblepharon and Trichiasis

    Published on: July 8, 2025

    637

    Related Experiment Videos

    Last Updated: Feb 19, 2026

    Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
    03:25

    Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy

    Published on: June 16, 2022

    1.4K
    Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
    09:41

    Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

    Published on: June 17, 2014

    12.5K
    Surgical Correction for Pediatric Epiblepharon and Trichiasis
    03:59

    Surgical Correction for Pediatric Epiblepharon and Trichiasis

    Published on: July 8, 2025

    637

    Area of Science:

    • Oncology
    • Immunology
    • Molecular Biology

    Background:

    • Ovarian cancer exhibits high malignancy and mortality, often associated with immunosuppression.
    • The precise mechanisms of ovarian cancer-induced immunosuppression remain unclear.
    • Herpesvirus entry mediator (HVEM) and B- and T-lymphocyte attenuator (BTLA) are known negative regulators of T-cell immune responses.

    Purpose of the Study:

    • To investigate the role of HVEM in ovarian cancer immunosuppression.
    • To explore the potential of targeting HVEM for ovarian cancer immunotherapy.

    Main Methods:

    • Quantification of HVEM mRNA in ovarian cancer tissues and cells.
    • Knockdown of HVEM expression in ovarian cancer cell lines (OVCAR3) using lentivirus-based small hairpin RNA (shRNA).
    • Assessment of cell proliferation, apoptosis, and cell cycle distribution.
    • Coculture experiments with activated T cells and HVEM-silenced ovarian cancer cells.

    Main Results:

    • HVEM mRNA levels were significantly elevated in ovarian cancer samples compared to benign tissues.
    • HVEM knockdown did not affect ovarian cancer cell proliferation, early apoptosis, or cell cycle.
    • HVEM-silenced ovarian cancer cells enhanced T-cell numbers and increased secretion of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ).
    • Activated T cells induced apoptosis in HVEM-silenced ovarian cancer cells.

    Conclusions:

    • Elevated HVEM expression contributes to immune escape mechanisms in ovarian cancer.
    • Targeting HVEM can restore anti-tumor immune responses by enhancing T-cell activity.
    • HVEM represents a promising target for novel ovarian cancer immunotherapies.